In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.
19 February 2014 | Eurekalert Medicine & Health
Wakonyo and her baby benefitted from Kenya’s successful drive to extend PMTCT, which nearly halved new infections among children between 2009 and 2011. But, worryingly, the drive is losing impetus. PMTCT coverage fell by 20 percent in 2011-2012, says the Progress Report 2013 of the Joint United Nations Programme on HIV/AIDS (UNAIDS).
29 January 2014 | Inter Press Service
Since July 2012, the Here I Am Campaign has been receiving stories from communities around the world, whose lives have been greatly impacted by the Global fund to fight AIDS, TB and Malaria. We initially set a goal to get 80 videos from around the world; we were overwhelmed by the responses.
04 December 2013 | Huffington Post
Uganda has gotten plenty of kudos and some criticism over its roll out of the new antiretroviral therapy for pregnant women and their babies, known as Option B +. Recommended by the World Health Organisation in June 2012, Option B+ consists in life-long provision of ARV therapy to pregnant women regardless of their CD4 count.
27 November 2013 | Inter Press Service
In February 2013, the Zimbabwe Ministry of Health and Child Welfare (MOHCW) decided to adopt Option B+ as its official PMTCT regimen.
10 September 2013 | Elizabeth Glaser Pediatric AIDS Foundation
Taking atazanavir as part of an antiretroviral regimen during pregnancy did not affect chances of hyperbilirubinemia in infants born to those mothers. UGT1A1 genotype correlated with hyperbilirubinemia in mothers but not in newborns.
06 September 2013 | International AIDS Society
Women living with HIV suffer from more intense hot flashes than those without the virus, with symptoms taking a more significant toll.
11 July 2013 | AIDSMeds
Option B+ is a prevention of vertical transmission approach for expectant mothers living with HIV in which women are immediately offered treatment for life regardless of their CD4 count. This approach offers advantages such as protection of partner(s) and (unborn) child, as well as benefits to the woman's health, but also carries with it risks. In the attached publication, GNP+ and ICW report on the results of 8 different focus group discussions that discussed these issues in Uganda and Malawi.
12 April 2013 | GNP+
Pregnant HIV-infected women treated with a lopinavir/ritonavir (Kaletra)-based antiretroviral regimen are at no greater risk of delivering a preterm baby than similar pregnant women given an efavirenz (Sustiva)-based treatment, researchers said here.
10 March 2013 | MedPage Today
A human rights investigation conducted by the Namibia Women’s Health Network, Harvard Law School’s Human Rights Program, and Northeastern University School of Law found that women living with HIV are often mistreated in hospital settings. This report will be launched at the AIDS conference this week in Washington DC.
25 July 2012 | 50.50